Myles HelfandExecutive Editor
Myles is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more -- and accumulating an ever-growing mountain of HIV conference badges along the way.
Latest by Myles Helfand
April 15, 2021: Alcohol and neurocognitive impairment; using hair analysis to measure substance use; integrase inhibitors' impact on verbal learning; hepatocellular carcinoma trends among PLWH.
Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
April 8, 2021: PrEP “contemplation” and uptake among adolescents; adolescent perception of HIV risk; HIV diagnosis rates among transgender people; PrEP and HIV incidence in Scotland.
April 1, 2021: The ethics of teaching U=U; the role of primary care in HIV service acceptance; STI testing rates in transgender women; the potential in anal self-sampling.
March 25, 2021: HIV disease progression spikes in a London hospital; neurocognitive impairment and frailty in PLWH; the smell of HIV-associated neurocognitive disorder; statin usage and physical function decline.
March 18, 2021: Improving viral suppression among PLWH experiencing homelessness; co-located PrEP services for trans women; subsidized health care and PrEP uptake; Heplisav-B hepatitis B vaccine efficacy in PLWH.
Our bite-sized study summaries include new research on antiretrovirals in development, trends in antiretroviral initiation speed and viral suppression rates in the U.S., and the link between gender-affirming surgery and an undetectable viral load.
There's new research on the risk of severe COVID-19 among people living with HIV, as well as prevention and treatment options.
March 11, 2021: Anticholinergic medications and neurocognitive issues; weight gain and dolutegravir in older men; drug interaction risks on B/F/TAF; real-world efficacy of HBV-active HIV treatment.
From new forms of PrEP to new data on HIV in the U.S., CROI 2021 has plenty of developments to report when it comes to preventing HIV and better understanding the drivers of the modern epidemic.